About this Session:
Developed in rapid response to the COVID-19 pandemic, Regeneron’s monoclonal antibody treatment is the result of Regeneron’s decades-long investment in scientific innovation and the creation of turnkey technologies, such as VelociSuite®. Join STAT’s Matt Herper for a behind-the-scenes conversation with George D. Yancopoulos, M.D., Ph.D., President and Chief Scientific Officer at Regeneron about how Regeneron built the scientific discovery engine that has helped fight diseases from EBOLA to COVID-19 – and the future of scientific innovation in a post-pandemic world.